Indian Company Master Data Made Simple
Search:
MCA
GSTIN
LEI
Udyam
Directors
36+ lakh companies in our registry
Natco Pharma Limited
Founded in 1981, Natco Pharma Limited has been operating for more than 45 years. Natco Pharma Limited holds the CIN L24230TG1981PLC003201 and registration number 3201. It falls under the category of company limited by shares. The company has an authorized share capital of ₹40.00 crore. Paid-up capital for the company equals ₹35.82 crore.
Its primary business activity involves manufacture of other chemical products. Registered under the jurisdiction of Hyderabad. The company’s incorporation address is Natco House , Road No.2, Banjara Hills, Hyderabad, Hyderabad, Telangana, India, 500034. Currently, the company’s operational status is active. Natco Pharma Limited holds PAN AAACN6927A. The firm is registered with LEI code 33580086GIBRWXSNGG39. For inquiries or official matters, please email investors@natcopharma.co.in. The company is led by Veera Venkata Narasimha Appa Rao Sannidhanam (CFO).
Company Overview
- CIN
- Date of Incorporation
- 18/09/1981
- Company Status
- Active
- RoC
- Hyderabad
- Registration Number
- Balance sheet date
- 31/03/2024
- Company Category
- Company limited by shares
- Company Sub Category
- Non-government company
- Listed in Stock Exchange
- Yes
- Class of Company
- Public Limited Company
- LEI Number
- LEI Status
- Issued
- Authorized Capital
- ₹40,00,00,000.00
- Paid up Capital
- ₹35,82,19,740.00
- Activity
- Manufacture of other chemical products
- investors@natcopharma.co.in
- PAN
GST Numbers
| State | GST Number | Status |
|---|---|---|
| Andhra Pradesh | 37AAACN6927A3ZM | Active |
| 37AAACN6927A1ZO | Active | |
| 37AAACN6927A2ZN | Active | |
| 37AAACN6927A4ZL | Inactive | |
| Assam | 18AAACN6927A5ZK | Inactive |
| 18AAACN6927A1ZO | Active | |
| 18AAACN6927A6ZJ | Active | |
| 18AAACN6927A3ZM | Inactive | |
| 18AAACN6927A2ZN | Inactive | |
| 18AAACN6927A4ZL | Inactive |
ISIN Numbers
| ISIN | Security | Interest Rate | Maturity Date | FISN | CFI |
|---|---|---|---|---|---|
| IN8987B01025 | NATCO PHARMA LIMITED EQ NEW FV RS. 2/- | - | 12/10/2026 | NATCO PHARMA/SH VTG | ESVUFN |
| INE987B01026 | NATCO PHARMA LIMITED EQ NEW FV RS. 2/- | - | 12/10/2026 | NATCO PHARMA/SH VTG | ESVUFN |
| INE987B20018 | NATCO PHARMA LIMITED REs - EQ RS. 2/- | - | 12/10/2026 | NATCO PHARMA/ENTL RT | RSSXXN |
Balance Sheet
| Metric | 31/03/2026 | 31/03/2025 | 31/03/2024 | 31/03/2023 | 31/03/2022 |
|---|---|---|---|---|---|
| Net PPE | ₹2,83,910.00L | ₹2,70,610.00L | ₹2,50,400.00L | ₹2,33,030.00L | ₹0.00L |
| Net Debt | ₹50,750.00L | ₹15,310.00L | ₹29,280.00L | ₹4,250.00L | ₹0.00L |
| Goodwill | ₹6,300.00L | ₹5,740.00L | ₹5,600.00L | ₹5,520.00L | ₹0.00L |
| Gross PPE | ₹2,83,910.00L | ₹3,95,560.00L | ₹3,56,780.00L | ₹3,24,260.00L | ₹0.00L |
| Inventory | ₹90,850.00L | ₹76,580.00L | ₹70,050.00L | ₹74,290.00L | ₹0.00L |
| Total Debt | ₹71,390.00L | ₹27,940.00L | ₹37,120.00L | ₹17,610.00L | ₹0.00L |
| Common Stock | ₹3,580.00L | ₹3,580.00L | ₹3,580.00L | ₹3,650.00L | ₹0.00L |
| Current Debt | ₹60,640.00L | ₹27,310.00L | ₹36,320.00L | ₹17,440.00L | ₹0.00L |
| Share Issued | ₹1,791.10L | ₹1,791.10L | ₹1,791.10L | ₹1,825.57L | ₹0.00L |
| Total Assets | ₹11,07,370.00L | ₹8,63,080.00L | ₹6,90,630.00L | ₹5,65,740.00L | ₹0.00L |
| Capital Stock | ₹3,580.00L | ₹3,580.00L | ₹3,580.00L | ₹3,650.00L | ₹0.00L |
| Long Term Debt | ₹10,000.00L | ₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L |
| Current Assets | ₹5,05,230.00L | ₹5,27,000.00L | ₹4,02,350.00L | ₹3,00,030.00L | ₹0.00L |
| Working Capital | ₹3,37,140.00L | ₹4,32,650.00L | ₹3,05,070.00L | ₹2,31,720.00L | ₹0.00L |
| Invested Capital | ₹9,92,750.00L | ₹7,88,010.00L | ₹6,21,630.00L | ₹5,04,820.00L | ₹0.00L |
| Other Properties | ₹2,54,540.00L | ₹4,740.00L | ₹5,030.00L | ₹4,500.00L | ₹0.00L |
| Common Stock Equity | ₹9,22,110.00L | ₹7,60,700.00L | ₹5,85,310.00L | ₹4,87,380.00L | ₹0.00L |
| Net Tangible Assets | ₹8,96,380.00L | ₹7,34,090.00L | ₹5,66,000.00L | ₹4,68,600.00L | ₹0.00L |
| Tangible Book Value | ₹8,96,380.00L | ₹7,34,090.00L | ₹5,66,000.00L | ₹4,68,600.00L | ₹0.00L |
| Current Liabilities | ₹1,68,090.00L | ₹94,350.00L | ₹97,280.00L | ₹68,310.00L | ₹0.00L |
| Long Term Provisions | ₹6,180.00L | ₹6,560.00L | ₹7,090.00L | ₹8,530.00L | ₹0.00L |
| Stockholders Equity | ₹9,22,110.00L | ₹7,60,700.00L | ₹5,85,310.00L | ₹4,87,380.00L | ₹0.00L |
| Other Equity Interest | ₹9,18,530.00L | ₹7,57,120.00L | ₹5,81,730.00L | ₹4,83,730.00L | ₹0.00L |
| Total Capitalization | ₹9,32,110.00L | ₹7,60,700.00L | ₹5,85,310.00L | ₹4,87,380.00L | ₹0.00L |
| Ordinary Shares Number | ₹1,791.10L | ₹1,791.10L | ₹1,791.10L | ₹1,824.70L | ₹0.00L |
| Other Intangible Assets | ₹19,430.00L | ₹20,870.00L | ₹13,710.00L | ₹13,260.00L | ₹0.00L |
| Other Non Current Assets | ₹6,990.00L | ₹4,900.00L | ₹6,940.00L | ₹2,710.00L | ₹0.00L |
| Total Non Current Assets | ₹6,02,140.00L | ₹3,36,080.00L | ₹2,88,280.00L | ₹2,65,710.00L | ₹0.00L |
| Cash And Cash Equivalents | ₹19,890.00L | ₹12,000.00L | ₹7,040.00L | ₹13,190.00L | ₹0.00L |
| Construction In Progress | ₹29,370.00L | ₹27,420.00L | ₹20,630.00L | ₹9,120.00L | ₹0.00L |
| Other Short Term Investments | ₹2,67,200.00L | ₹2,68,760.00L | ₹1,70,560.00L | ₹99,290.00L | ₹0.00L |
| Goodwill And Other Intangible Assets | ₹25,730.00L | ₹26,610.00L | ₹19,310.00L | ₹18,780.00L | ₹0.00L |
| Total Equity Gross Minority Interest | ₹9,22,110.00L | ₹7,61,230.00L | ₹5,85,310.00L | ₹4,87,380.00L | ₹0.00L |
| Total Liabilities Net Minority Interest | ₹1,85,260.00L | ₹1,01,850.00L | ₹1,05,320.00L | ₹78,360.00L | ₹0.00L |
| Current Debt And Capital Lease Obligation | ₹60,970.00L | ₹27,480.00L | ₹36,590.00L | ₹17,500.00L | ₹0.00L |
| Long Term Debt And Capital Lease Obligation | ₹10,420.00L | ₹460.00L | ₹530.00L | ₹110.00L | ₹0.00L |
| Cash Cash Equivalents And Short Term Investments | ₹2,87,090.00L | ₹2,80,760.00L | ₹1,77,600.00L | ₹1,12,480.00L | ₹0.00L |
| Total Non Current Liabilities Net Minority Interest | ₹17,170.00L | ₹7,500.00L | ₹8,040.00L | ₹10,050.00L | ₹0.00L |
Cash Flow
| Metric | 31/03/2026 | 31/03/2025 | 31/03/2024 | 31/03/2023 | 31/03/2022 |
|---|---|---|---|---|---|
| Free Cash Flow | ₹1,37,720.00L | ₹1,18,520.00L | ₹85,290.00L | ₹64,350.00L | ₹0.00L |
| Changes In Cash | -₹1,590.00L | ₹7,160.00L | -₹6,800.00L | ₹900.00L | ₹0.00L |
| End Cash Position | ₹19,890.00L | ₹12,000.00L | ₹7,040.00L | ₹13,190.00L | ₹0.00L |
| Financing Cash Flow | ₹29,750.00L | -₹21,070.00L | -₹24,690.00L | -₹36,300.00L | ₹0.00L |
| Investing Cash Flow | -₹2,08,170.00L | -₹1,41,450.00L | -₹1,03,270.00L | -₹47,710.00L | ₹0.00L |
| Operating Cash Flow | ₹1,76,830.00L | ₹1,69,680.00L | ₹1,21,160.00L | ₹84,910.00L | ₹0.00L |
| Capital Expenditure | -₹39,110.00L | -₹51,160.00L | -₹35,870.00L | -₹20,560.00L | ₹0.00L |
| Beginning Cash Position | ₹12,000.00L | ₹7,040.00L | ₹13,190.00L | ₹11,110.00L | ₹0.00L |
| Issuance Of Capital Stock | ₹0.00L | ₹730.00L | ₹0.00L | ₹0.00L | ₹0.00L |
Income Statement
| Metric | 31/03/2026 | 31/03/2025 | 31/03/2024 | 31/03/2023 | 31/03/2022 |
|---|---|---|---|---|---|
| EBIT | ₹1,52,750.00L | ₹2,31,530.00L | ₹1,68,550.00L | ₹87,140.00L | ₹0.00L |
| EBITDA | ₹1,73,410.00L | ₹2,55,050.00L | ₹1,87,230.00L | ₹1,03,520.00L | ₹0.00L |
| Net Income | ₹1,41,850.00L | ₹1,88,540.00L | ₹1,38,830.00L | ₹71,530.00L | ₹17,000.00L |
| Gross Profit | ₹3,38,780.00L | ₹3,73,970.00L | ₹3,11,630.00L | ₹1,95,140.00L | ₹0.00L |
| Pretax Income | ₹1,49,080.00L | ₹2,29,140.00L | ₹1,67,350.00L | ₹86,190.00L | ₹0.00L |
| Tax Provision | ₹11,890.00L | ₹40,800.00L | ₹28,520.00L | ₹14,660.00L | ₹0.00L |
| Total Revenue | ₹4,07,830.00L | ₹4,42,950.00L | ₹3,97,880.00L | ₹2,69,690.00L | ₹1,94,480.00L |
| Cost Of Revenue | ₹69,050.00L | ₹68,980.00L | ₹86,250.00L | ₹74,550.00L | ₹0.00L |
| Total Expenses | ₹2,84,840.00L | ₹2,46,870.00L | ₹2,40,200.00L | ₹1,90,680.00L | ₹0.00L |
| Interest Expense | ₹3,670.00L | ₹2,390.00L | ₹1,200.00L | ₹950.00L | ₹0.00L |
| Operating Income | ₹1,22,990.00L | ₹1,96,080.00L | ₹1,57,680.00L | ₹79,010.00L | ₹0.00L |
| Tax Rate For Calcs | ₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L |
| Normalized EBITDA | ₹1,73,410.00L | ₹2,55,050.00L | ₹1,87,980.00L | ₹1,03,570.00L | ₹0.00L |
| Normalized Income | ₹1,41,850.00L | ₹1,88,540.00L | ₹1,39,452.18L | ₹71,571.50L | ₹0.00L |
| Operating Expense | ₹2,15,790.00L | ₹1,77,890.00L | ₹1,53,950.00L | ₹1,16,130.00L | ₹0.00L |
| Operating Revenue | ₹4,07,830.00L | ₹4,42,950.00L | ₹3,99,880.00L | ₹2,69,690.00L | ₹0.00L |
| Net Interest Income | -₹3,670.00L | -₹2,390.00L | ₹8,180.00L | ₹3,670.00L | ₹0.00L |
| Other Operating Expenses | ₹1,26,410.00L | ₹94,920.00L | ₹43,160.00L | ₹22,260.00L | ₹0.00L |
| Reconciled Depreciation | ₹20,660.00L | ₹23,520.00L | ₹18,680.00L | ₹16,380.00L | ₹0.00L |
| Reconciled Cost Of Revenue | ₹69,050.00L | ₹68,980.00L | ₹86,250.00L | ₹74,550.00L | ₹0.00L |
| Tax Effect Of Unusual Items | ₹0.00L | ₹0.00L | -₹127.82L | -₹8.50L | ₹0.00L |
| Interest Expense Non Operating | ₹3,670.00L | ₹2,390.00L | ₹1,200.00L | ₹950.00L | ₹0.00L |
| Net Income Common Stockholders | ₹1,41,850.00L | ₹1,88,540.00L | ₹1,38,830.00L | ₹71,530.00L | ₹0.00L |
| Net Income Continuous Operations | ₹1,41,850.00L | ₹1,88,340.00L | ₹1,38,830.00L | ₹71,530.00L | ₹0.00L |
| Diluted NIAvailto Com Stockholders | ₹1,41,850.00L | ₹1,88,540.00L | ₹1,38,830.00L | ₹71,530.00L | ₹0.00L |
| Otherunder Preferred Stock Dividend | ₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L | ₹0.00L |
| Net Non Operating Interest Income Expense | -₹3,670.00L | -₹2,390.00L | ₹8,180.00L | ₹3,670.00L | ₹0.00L |
| Net Income Including Noncontrolling Interests | ₹1,41,850.00L | ₹1,88,340.00L | ₹1,38,830.00L | ₹71,530.00L | ₹0.00L |
| Net Income From Continuing And Discontinued Operation | ₹1,41,850.00L | ₹1,88,540.00L | ₹1,38,830.00L | ₹71,530.00L | ₹0.00L |
| Net Income From Continuing Operation Net Minority Interest | ₹1,41,850.00L | ₹1,88,540.00L | ₹1,38,830.00L | ₹71,530.00L | ₹0.00L |
Company Performance (FY22–FY26)
₹4.4 K Cr₹3.3 K Cr₹2.2 K Cr₹1.1 K Cr₹0
FY22FY23FY24FY25FY26
Directors
| Appointment | Director name | DIN | Designation | |
|---|---|---|---|---|
| 01/06/2012 | Rajeev Nannapaneni | 00183872 | Whole-time director | View other directorships |
| 12/11/2014 | Potluri Prasad Sivaramakrishna | 07011140 | Whole-time director | View other directorships |
| 11/02/2015 | Lingarao Donthineni | 07088404 | Whole-time director | View other directorships |
| 01/04/2015 | Venkaiah Chowdary Nannapaneni | 00183315 | Managing Director | View other directorships |
| 11/02/2016 | Veera Venkata Narasimha Appa Rao Sannidhanam | *****5964Q | CFO | |
| 01/04/2022 | Venkat Ramesh Chekuri | *****3380L | Company Secretary | |
| 09/08/2022 | Ganapati Bhat Pavan | 09691260 | Whole-time director | View other directorships |
| 01/04/2024 | Agnihotra Dakshina Murty Chavali | 00374673 | Director | View other directorships |
| 01/04/2024 | Vijayabhaskar Dronadula | 07158951 | Director | View other directorships |
| 12/08/2024 | Nitin Jain | 00136245 | Director | View other directorships |
| 12/08/2024 | Suma Kantipudi | 02734369 | Director | View other directorships |
| 12/08/2024 | Lakshminarayana Bolisetty | 02766709 | Director | View other directorships |
Business Network
CompanyDirectorNot on WeeDooBoard seatKey rolePast seatOwnership
Directors 12
- Venkaiah Chowdary NannapaneniManaging Director
- Ganapati Bhat PavanWhole-time director
- Lingarao DonthineniWhole-time director
- Potluri Prasad SivaramakrishnaWhole-time director
- Rajeev NannapaneniWhole-time director
- Lakshminarayana BolisettyDirector
- Nitin JainDirector
- Suma KantipudiDirector
- Agnihotra Dakshina Murty ChavaliDirector
- Vijayabhaskar DronadulaDirector
- Venkat Ramesh ChekuriCompany Secretary
- Veera Venkata Narasimha Appa Rao SannidhanamCFO
Subsidiaries 1
- Natco Pharma (canada) Inc.Direct
Latest Documents
Category:
| Date | Title | Size |
|---|---|---|
| 10/12/2024 | Form Addendum to AOC-4 CSR-10122024_signed | - |
| 22/11/2024 | Form MGT-7-22112024 | - |
| 11/11/2024 | Form AOC-4(XBRL)-02112024 | - |
| 22/03/2024 | Form Addendum to AOC-4 CSR-22032024_signed | - |
Similar Companies
| Company | CIN | Address |
|---|---|---|
| Dabur India Limited | L24230DL1975PLC007908 | 8/3 Asaf Ali Road, New Delhi, Delhi, India, 110002 |
| Gujchem Distillers India Limited | L24230GJ1939PLC002480 | - |
| Ind Swift Limited | L24230CH1986PLC006897 | 781industrial Area Phase Ii, Chandigarh, Chandigarh, India, 160002 |
| Lyka Labs Limited | L24230GJ1976PLC008738 | 4801/b & 4802/a Gidc Indutrail Estate, Ankleshwar, Gujarat, India, 393002 |
| Torrent Pharmaceuticals Ltd | L24230GJ1972PLC002126 | Torrent Houseoff Ashram Road Navarangpura 9, Ahmedabad, Gujarat, India, 000000 |
Direct/Ultimate Children
| Type | Legal Name | LEI code |
|---|---|---|
| Direct | Natco Pharma (canada) Inc. | 89450030UPOKGX7IJ249 |
Address
Natco House , Road No.2, Banjara Hills, Hyderabad, Hyderabad, Telangana, India, 500034
Frequently Asked Questions
What is the incorporation date of Natco Pharma Limited?
The incorporation date of Natco Pharma Limited is 18/09/1981.
What is the authorized share capital and paid-up capital of Natco Pharma Limited?
The authorized share capital of Natco Pharma Limited is ₹40,00,00,000.00. The paid-up capital is ₹35,82,19,740.00.
Who are the current board members & directors of Natco Pharma Limited?
The current board member of Natco Pharma Limited are:
- Rajeev Nannapaneni
- Rajeev Nannapaneni
- Lingarao Donthineni
- Venkaiah Chowdary Nannapaneni
- Potluri Prasad Sivaramakrishna
- Ganapati Bhat Pavan
- Nitin Jain
- Suma Kantipudi
- Lakshminarayana Bolisetty
- Agnihotra Dakshina Murty Chavali
- Vijayabhaskar Dronadula
What is the registered address of Natco Pharma Limited?
The registered address of Natco Pharma Limited is Natco House , Road No.2, Banjara Hills, Hyderabad, Hyderabad, Telangana, India, 500034.
What is the Corporate Identification Number of Natco Pharma Limited?
The Corporate Identification Number of Natco Pharma Limited is L24230TG1981PLC003201.